MUC1 and neoplasm: For example, Sucheck et al. synthesized a cancer vaccine conjugate (Pam3CysSK4-DBCO-MUC1-VNTR-TACA) (Figure 4f) containing Pam3CysSK4, a TLR agonist, linked via copper-free cycloaddition chemistry to a glycopeptide derived from the tumor marker MUC-1 also holding the Tn-antigen [62].